MedTrace Logo

Genetic Analysis Between Charlotte's Web Responders Versus Non- Responders in a Dravet Population

NCT02229032 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 19

Last updated 2017-12-15

No results posted yet for this study

Summary

There is tremendous curiosity about medical marijuana and the treatment of epilepsy. In a specific genetic epilepsy known as Dravet Syndrome, a mutation occurs affecting the SCN1A gene. A specific strain of marijuana known as Charlotte's Web, available in Colorado, may have activity in this catastrophic epilepsy syndrome. Anecdotal reports suggest both success and lack of response with this therapy. Genetic analysis of the differences between Dravet responders and non-responders may prove useful for identifying patients likely to be helped by this therapy, as well as shed light on the putative mechanisms by which marijuana may exert any antiepileptic effect.

Conditions

Sponsors & Collaborators

  • Denver Health Medical Center

    collaborator OTHER

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Edward Maa, MD · Denver Health Medical Center

Eligibility

Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2017-07-31
Completion
2017-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02229032 on ClinicalTrials.gov